Memo Therapeutics AG宣布,公司将采用其专有的Dropzylla技术平台,开展重组多克隆免疫球蛋白G(IgG)的研发工作。该平台具备克隆抗体库及表达抗体的核心功能,有望推动新一代抗体疗法的创新突破。
Memo Therapeutics AG宣布,公司将采用其专有的Dropzylla技术平台,开展重组多克隆免疫球蛋白G(IgG)的研发工作。该平台具备克隆抗体库及表达抗体的核心功能,有望推动新一代抗体疗法的创新突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.